'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan (2)

STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

Related Keywords

South Korea ,Japan ,Switzerland ,Stockholm ,Sweden ,Canada ,United Kingdom ,China ,Uppsala ,Uppsala Lan ,Australia ,Israel ,Japanese ,Great Britain ,Swedish ,Oskar Bosson ,Jiang Millington ,Gunilla Osswald ,Washington University School Of Medicine ,Alzheimer Network Trials Unit ,Alzheimer Clinical Trial Consortium ,Japanese Ministry Of Health ,National Institute On ,Drug Administration ,Uppsala University ,Vp Communications ,Ad Cooperative Study ,National Institutes Of Health ,Nasdaq Stockholm ,Clinical Dementia Rating Sum ,Daily Living Scale ,Mild Cognitive Impairment ,Clinical Trials ,New England Journal ,Japanese Ministry ,Biogen Japan ,Marketing Authorization ,Director Corporate Communication ,Social Mediae Mail ,Dose Management ,Antithrombotic Medication ,Risk Factors ,Intracerebral Hemorrhage ,Innovative Licensing ,Access Pathway ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Commercialization Agreement ,Nasdaq Stockholm Large Cap ,